| |
著者: Annika Söderbergh, Anne Grethe Myhre, Olov Ekwall, Gennet Gebre-Medhin, Håkan Hedstrand, Eva Landgren, Aaro Miettinen, Petra Eskelin, Maria Halonen, Tiinamaija Tuomi, Jan Gustafsson, Eystein S Husebye, Jaakko Perheentupa, Mikhail Gylling, Michael P Manns, Fredrik Rorsman, Olle Kämpe, Thomas Nilsson
雑誌名: J Clin Endocrinol Metab. 2004 Feb;89(2):557-62. doi: 10.1210/jc.2003-030279.
Abstract/Text
The prevalence of autoantibodies against nine intracellular enzyme autoantigens, namely 21-hydroxylase, side-chain cleavage enzyme (SCC), 17 alpha-hydroxylase, glutamic acid decarboxylase 65, aromatic L-amino acid decarboxylase, tyrosine phosphatase-like protein IA-2, tryptophan hydroxylase (TPH), tyrosine hydroxylase, cytochrome P450 1A2, and against the extracellular calcium-sensing receptor, was assessed in 90 patients with autoimmune polyendocrine syndrome type I. A multivariate logistic regression analysis was performed for the presence of autoantibodies as independent predictors for different disease manifestations. Reactivities against 21-hydroxylase and SCC were associated with Addison's disease with odds ratios (ORs) of 7.8 and 6.8, respectively. Hypogonadism was exclusively associated with autoantibodies against SCC with an OR of 12.5. Autoantibodies against tyrosine phosphatase-like protein IA-2 were associated with insulin-dependent diabetes mellitus with an OR of 14.9, but with low sensitivity. Reactivities against TPH and, surprisingly, glutamic acid decarboxylase 65, were associated with intestinal dysfunction, with ORs of 3.9 and 6.7, respectively. TPH reactivity was the best predictor for autoimmune hepatitis, with an OR of 27.0. Hypoparathyroidism was not associated with reactivity against any of the autoantigens tested. No reactivity against the calcium-sensing receptor was found. Analysis of autoantibodies in autoimmune polyendocrine syndrome type I patients is a useful tool for establishing autoimmune manifestations of the disease as well as providing diagnosis in patients with suspected disease.
PMID 14764761 J Clin Endocrinol Metab. 2004 Feb;89(2):557-62. doi: 10.1210/jc.2003-030279.
|
